Single dose administration of beta-adrenoceptor agonists produces bronchodilation and inhibits AHR, and is the standard treatment for the acute relief of asthma. However, chronic repetitive administration of beta-adrenoceptor agonists may increase AHR, airway inflammation, and risk of death. Based upon the paradigm shift that occurred with the use of beta-blockers in congestive heart failure, we previously determined that chronic administration of beta-blockers decreased AHR in a murine model of asthma. To elucidate the mechanisms for the beneficial effects of beta-blockers, we examined the effects of chronic administration of several beta-adrenoceptor ligands in a murine model of allergic asthma.
Asthma mortality rates in the U.S. have risen by 60% in the last 25 years despite the widespread chronic therapeutic use of beta-adrenoceptor agonists (1) . Recently, a large clinical trial using a longacting beta-adrenoceptor agonist, salmeterol, was stopped due to an increased incidence of death and serious asthma-related events (2) . Clearly there is a need for a different approach to chronic asthma therapy. Analogous to asthma, a different approach was needed in congestive heart failure (CHF) because the administration of beta-adrenoceptor agonists also produced acutely beneficial but chronically detrimental effects (3) . Recently, drugs classified as beta-blockers (beta-adrenoceptor antagonists and inverse agonists) were introduced into therapy for CHF and have now become a part of first-line therapy (4) . These drugs were once contraindicated in CHF because acute administration produced negative inotropic effects and decreased cardiac output (3) . However, large clinical trials have shown that chronic administration improved cardiac output and decreased mortality in patients with CHF (4, 5) . Notably, chronic administration of beta-blockers with partial agonist properties did not decrease mortality in CHF (6) (7) (8) .
Presently, the administration of beta-blockers is contraindicated in asthma because their acute administration may cause increased airway resistance (9, 10) . The effects of chronic administration of beta-blockers in asthma have not been closely examined, perhaps because of the assumption that the chronic and acute effects of these drugs are similar (3, 11, 12) . To determine if the assumption is incorrect, we previously investigated whether chronic administration of beta-blockers with inverse agonist properties could be useful in treating asthma. Beta-adrenoceptor inverse agonists are a subset of beta-blockers, that like all beta-blockers can inhibit agonist-induced signaling, but inverse agonists can also inhibit signaling produced by constitutively active receptors (13) . For the parameters that have been examined, agonists and inverse agonists produce the exact opposite effects (14) . We therefore hypothesized that the reciprocal effects of agonists and inverse agonists may extend to their effect on signaling (14) ; specifically, that chronic agonist exposure can produce desensitization and inhibit signaling, while chronic treatment with inverse agonists may produce sensitization and enhance signaling. Our initial studies using a murine model of asthma showed that acute administration of beta-blockers with inverse agonist properties was detrimental and increased AHR, but chronic administration significantly decreased AHR (15) . These data indicate the important role that duration of drug therapy can have on the observed physiological or clinical response. Further support for our hypothesis is that as with CHF, chronic administration of a beta-blocker with partial agonist properties did not decrease AHR in the murine model of asthma (6) (7) (8) 15) .
In this study we have examined the effect of chronic treatment with beta-blockers on airway inflammation in an antigen-driven murine model of asthma. The inflammatory process in asthma involves the interaction between different immune cells such as lymphocytes and eosinophils, and parenchymal cells such as airway epithelial and smooth muscle cells. The nature of the interaction between these cells contributes to airflow obstruction, bronchoconstriction (including AHR), airway edema, goblet cell hyperplasia and mucin hypersecretion (16, 17) . Here we specifically measured the number of inflammatory cells and the level of the cytokines IL-13, IL-10, IL-5, transforming growth factor-β1 (TGF-β1), and regulated on activation T cell expressed and secreted (RANTES) in bronchoalveolar lavage fluid, and determined the degree of mucous metaplasia by airway epithelial cells.
MATERIALS AND METHODS

Mice
6 to 12 week old BALB/cJ (male) mice (Jackson Animal Laboratory, Bar Harbor, ME) and C57BL/6J 
Animal Sensitization and Challenge
In the first set of experiments with BALB/cJ mice ( Figure 1, protocol 1) , antigen-challenged animals were sensitized (3 intraperitoneal OVA injections weekly on days 0, 7, and 14) and challenged (once daily intranasally for 5 days on days 23-27) with ovalbumin (OVA) as previously described (18). In the second set of experiments ( Figure 1 , protocol 2), antigen-challenged BALB/cJ mice were sensitized (weekly intraperitoneal injections, on days 0, 7, and 14) and challenged (once daily intranasally for 5 days on days 41-45) with OVA. Thus, the only difference between the two protocols was the time of challenge relative to the sensitization injections. Control mice received OVA during sensitizations and saline during the challenges. Because our results were unexpected, a second laboratory performed the experiments using C57BL/6J mice and a different sensitization and challenge protocol ( Figure 1 , protocol 3). Antigen-challenged C57BL/6J mice were sensitized (intraperitoneal OVA injection 4 times, weekly on day 0, 7, 14, and 21) and challenged (2 times, on day 35 and 38) with aerosolized OVA (19) .
Drug Administration
The beta-blockers ICI 118,551 and nadolol were chosen because a previous study using transgenic mice with cardiac over-expression of the human beta 2 -adrenoceptor revealed these two drugs to be full inverse agonists at this receptor (13) . However, nadolol has equal affinity for both beta 1 -and beta 2 -adrenoceptors, while ICI 118,551 has a ~3,000 selectivity for the beta 2 -adrenoceptor. In the first set of experiments ( Figure 1, protocol 1) , a group of antigen-challenged BALB/cJ mice were fed (ad 6 libitum) mouse chow containing the non-selective beta-adrenoceptor antagonist nadolol (13 
Bronchoalveolar Lavage
Cold phosphate buffered saline (1 ml PBS) was infused and drawn back through the tracheal cannula from euthanized (pentobarbital 0.1 ml of 65 mg/ml) BALB/cJ mice, and repeated once. The total leukocyte count in the brochoalveolar lavage (BAL) was determined using a Coulter counter.
Cytospins were prepared from 200 μl of BAL at 500 rpm for 5 min and stained with Hema-3 for enumeration of cell types. Eosinophils, monocytes, lymphocytes, or neutrophils were identified by standard morphologic criteria. At least 200 cells were counted from cytospin preparations. BAL was also obtained as described above through the tracheal cannula in euthanized C57BL/6J mice. The total leukocyte count was determined using a hemacytometer, and cell populations were determined by cytocentrifugation of 300 μl of BAL using a Cytospin 4 (Thermo Electron Corporation, Waltham, MA) at 2,000 rpm for 5 min, followed by Wright-Giemsa staining.
Histochemistry
For staining with periodic acid fluorescent Schiff's (PAFS) reagent to examine intracellular mucin, lungs were fixed with 4% paraformaldehyde in PBS (pH 7.0) infused through a tracheal cannula at room temperature, then removed from the thoracic cavity and further fixed overnight at 4ºC, embedded in paraffin, sectioned and stained for light microscopy as previously described (19) .
Fluorescence Microscopy
For the quantification of mucin, PAFS-stained slides were examined under a 40X objective. Images of 10 fields from the axial bronchi were captured, and camera settings were managed using MagnaFire 2.1 (Optronics) (19) . The volume density of mucin in the airway epithelium was then measured using ImagePro Plus and calculated as previously described (19) . Images were acquired prior to any measurements and analyzed by blinded investigators.
Immunohistochemistry
Immunohistochemical staining was performed on 5 μm paraffinized sections of C57BL/6J mice lung tissue after paraformaldehyde (Sigma) fixation. Sections dewaxed with xylene (Sigma-Aldrich) were placed in 100% ethanol for 2 x 5 min, followed by 3% H 2 O 2 (Sigma) in methanol for 10 min to quench endogenous peroxidase activity, and then fully rehydrated. Antigen retrieval was performed in citrate buffer 10 mM, pH 6.0 for 10 min at 100ºC. Goat serum (Vector Laboratories) diluted in PBS was used to block nonspecific binding sites. For Muc5AC, the primary antibody used was chicken polyclonal anti-Muc5AC (20) at a 1:2000 dilution. After 1 h incubation at 23ºC, the biotinylated secondary antibody goat Anti-chicken (Invitrogen) was applied at 1:500 for 30 min at 23ºC. For Muc5B, primary antibody used was rabbit anti-Muc5B (from Camille Ehre) at 1:10000 for 1 h at 23ºC followed by incubation with secondary antibody goat anti-rabbit-HRP at 1:200 for 30 min at 23ºC for 30 min. The
Muc5B antibody was raised against a 15aa synthetic peptide corresponding to a sequence that was repeated 6 times in the tandem repeats of Muc5b between aa1560 and aa3370. Bound antibody was visualized using the Vectastain ABC staining kit (Vector Laboratories). Slides were examined under a 60X objective. and Muc5b (Assay Mm 00466376 m1), and VIC dye-labeled TaqMan probe for 18S (Assay 4319413E). Quantitative PCR was performed using 100 ng of cDNA in a 20 μl reaction, using an ABI PRISM 7000 Sequence Detection System (Applied Biosystems). A standard curve was generated by running in parallel synthetic single stranded oligonucleotide templates for each transcript at dilutions of 10 to 0.001nM. The results were expressed as number of mucin gene copies per 18S copies.
RNA Isolation and RT-PCR
Cytokine and Chemokine Levels
The levels of IL-13, IL-10, IL-5, TGF-β1, and RANTES in BAL obtained 24 hrs after the last antigen challenge were measured by Pierce Searchlight®, (Woburn, MA) using multiplex ELISA. The samples were provided to Pierce Searchlight® in blinded fashion.
Statistical Analysis
Quantitative data are presented as mean ± standard error of the mean (SEM; expressed as the percent standard error of the mean). Statistical analysis for multiple groups was performed using one-way analysis of variance followed by Dunnett's multicomparison test. Unpaired t-test was performed for analysis of two groups (Prism, GraphPad software, CA). P < 0.05 was considered statistically significant.
RESULTS
Chronic Administration of Beta-Blockers Reduces Airway Eosinophilia and Cytokine Levels
The total cell count in bronchoalveolar lavage (BAL) was greatly increased in antigen-challenged immunized BALB/cJ mice compared with saline-challenged mice (Figure 2A ) 
Chronic Administration of Beta-Blockers Attenuates Airway Epithelial Cell Mucin Production
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To determine whether chronic administration of beta-blockers affects mucin content, sections from the axial bronchi of experimental mice were assessed using PAFS staining. 
Chronic Administration of Beta-Blockers during the Challenge Phase Alone Reduces Airway
Inflammation and Mucin Production
In our initial experiments, the 28 day administration of beta-adrenoceptor ligands (salbutamol, ICI 118,551, or nadolol) occurred during both the OVA sensitization and challenge phases ( Figure 1 , protocol 1). To determine which phase is critically affected by beta-blockers, a second set of experiments was performed in which exposure to the beta-adrenoceptor ligands was begun after completion of the sensitization process ( Figure 1, protocol 2) . Administration of beta-blockers for 28 days beginning after the completion of sensitization produced similar reductions in mucous metaplasia (compare Figure 4B , protocol 1 and 2), thus ruling out interference by the betaadrenoceptor ligands with the sensitization process as a cause of the observed decreases in mucous metaplasia. Furthermore, the administration of ICI 118,551 for 7 days beginning after the completion of sensitization reduced BAL total cell counts from 10.4 x 10 5 ± 13.6% to 5.4 x 10 5 ± 16.6% (n = 5-12, P < 0.05), a reduction very similar in degree to that observed with the administration of beta-blockers for 28 days during both sensitization and challenge ( Figure 2) . Also, the results with C57BL/6J mice, in which exposure to ICI 118,551 occurred after completion of the sensitization process ( Figure 1,   protocol 3) , parallel the results observed in the BALB/cJ mice. Surprisingly, 7 days of beta-blocker during the challenge phase alone did not reduce mucous metaplasia to the same extent as 28 days of beta-blocker during the challenge phase ( Figure 4B , protocol 2). Decreased mucin production was confirmed by immunohistochemical staining in C57BL/6J mice ( Figure 5A ) and by quantification of Muc5ac transcripts in both C57BL/6J and BALB/cJ mice ( Figure 5B ). Muc5AC is the predominant mucin upregulated in airway epithelial cells in patients with asthma and in the ovalbumin mouse models of asthma (21, 22) . The results show that Muc5AC staining and transcripts are markedly increased in antigen-challenged mice compared to saline-challenged mice, but both are decreased in antigen-challenged mice treated with nadolol (28 days) ( Figure 5 ). We also performed immunohistochemical staining ( Figure 5A ) and quantification of transcripts for Muc5b ( Figure 5B ).
This mucin does not change substantially in antigen-induced mucous metaplasia (21, 22) , and, as expected, antigen sensitization and challenge produced only a small change in Muc5B expression and transcripts, and these levels were not affected by treatment with nadolol ( Figure 5 ).
DISCUSSION
Based on the paradigm shift that occurred in the treatment of heart failure with regards to betaadrenoceptor drugs, we hypothesized that chronic beta-blocker treatment may be beneficial in asthma (12, 15) . Here we report that chronic treatment with 'beta-blockers', a class of drugs currently contraindicated in asthma, reduces airway inflammation in a murine model of asthma. A characteristic feature of asthma is the airway infiltration by inflammatory cells such as lymphocytes 13 and eosinophils (16, 17) . These cells produce a wide range of inflammatory mediators and cytotoxic proteins that are responsible for the perpetuation of airway inflammation (16, 17) . Our results show that chronic treatment with nadolol or ICI 118,551 reduced the inflammatory cells in the bronchoalveolar lavage of antigen-challenged mice (Figure 2) , and nadolol also reduced the levels of the cytokines IL-13, IL-10, IL-5, and TGF-β1 (Figure 3) . The ~50% reduction in eosinophils in BAL
was comparable to what we had previously reported, although in that study the reduction did not reach statistical significance (P=0.07) (15) . The effect of beta-blockers on BAL cellularity was not confined to one strain of mice, since it was observed in both BALB/cJ and C57BL/6J mice. The results with C57BL/6J mice were performed by another laboratory using a slightly different sensitization and challenge protocol. Thus the effect of beta-blockers appears to be robust and relatively insensitive to experimental conditions.
The reduction in inflammatory cells and cytokines caused by chronic administration of betablockers suggested that target effects of airway inflammation might also be reduced by this drug treatment. We therefore asked whether chronic administration of beta-blockers affected airway epithelial cell morphology and mucin content (17) . The airway epithelium is a mechanical barrier that protects the underlying tissue from the external environment (23), but also shows great plasticity in structure and function (24) (25) (26) . In asthma, the airway epithelium contains increased numbers of goblet cells filled with mucus, which contributes significantly to airflow obstruction and asthma morbidity (24, (26) (27) (28) . At a molecular level, upregulation of Muc5AC gene expression is the central event in mucous metaplasia (21) . Chronic treatment with beta-blockers produced a marked time-dependent decrease in goblet cell numbers and mucin content of the airway epithelium (Figures 4 and 5) . The effect of nadolol showed selectivity for Muc5AC staining and mRNA, as Muc5B, a polymeric mucin not substantially involved in the antigen-induced mucous metaplasia was not affected by nadolol 14 administration ( Figure 5 ) (22) . The reduction in mucous metaplasia was not due to interference with the sensitization process as the results were the same when treatment was begun after the sensitization process was complete ( Figure 4 , and the reduction in mucous metaplasia observed in the C57BL/6J mice). Furthermore, there was no significant change in serum IgE levels following chronic nadolol treatment (data not shown), which also suggests a lack of interference with the sensitization process.
The fact that the principal effect of beta-blockers is exerted during the challenge rather than the sensitization phase of our asthma models, and that the reduction in mucous metaplasia from betablockade is disproportionate to the reduction in lung inflammatory cells, suggests that beta-blockers exert an important effect on the epithelium itself. Supporting this hypothesis is that chronic exposure to beta-blockers has been shown to produce a marked increase in beta 2 -adrenoceptor numbers primarily in airway epithelial cells (29) , and that over-expression of the beta 2 -adrenoceptors in the airway epithelium reduces AHR (30) . In our murine model of asthma, AHR reduction does parallel the reduction in BAL cellularity and also the mucin data to an extent. However, there are also differences.
In experiments run in parallel to these but published separately (29) , the observed reduction in AHR is maximal after 7 days of treatment with a beta-blocker (29) and stays reduced to the same extent at 28 days, thus following a time course similar to the cells and eosinophils in BAL, while the mucous metaplasia, though significantly reduced at 7 days, continues to decline further with 28 days of betablocker treatment. Comparing the effects of 7 days versus 28 days of beta-blocker treatment suggests that the reduction in mucous metaplasia from beta-blockade does not reach steady state after 7 days and suggests that there are complex effects on epithelial cell signaling (24, 26) . Mucous metaplasia is a cardinal feature of the asthma phenotype that is thought to play a central role in death from asthma (24, 25, 31) . Recent studies also suggest that mucin hypersecretion can contribute 15 significantly to AHR (27, 32, 33) . Thus, the finding that chronic administration of beta-blockers reduces mucin content in airway epithelial cells suggests a possible identification of a cell type involved in the decreased AHR that we previously observed (15) .
Together, these observations of the anti-inflammatory effect of beta-blockers in a murine model of asthma, suggests that asthmatics may benefit from treatment with such drugs given their ability to reduce some indices of airway inflammation and to further reduce mucous metaplasia. Indeed, in a small (10 patients) clinical trial, treatment of mild asthmatics with nadolol for 9 weeks resulted in a dose-dependent increase in the concentration of methacholine required to produce a 20% fall in forced expiratory volume at 1 second (PC 20 methacholine value) (34) .
In addition to investigating the differences we observed on mucous metaplasia between 28 and 7 days of treatment, future studies will explore differences in the changes produced by nadolol and other beta-blockers. So far, different effects on airway resistance have been observed for various beta-blockers (15) , and whether all beta-blockers confer equal benefit in asthma therapy would be a subject of importance. Within the limitations of extrapolating from a murine model of asthma, these results provide a second disease model besides heart failure where compounds producing an acutely detrimental effect may provide a therapeutically beneficial effect with chronic administration, and indicate that the chronic effect of drugs cannot be predicted from their acute effects (11, 12) .
Furthermore, similar to the paradigm shift in the treatment of heart failure, our current results with beta-blockers could potentially lead to another paradigm shift in the treatment of another important disease, asthma. 
